Eisai news from FiercePharma
NewsFalling dollar, falling drugmaker prices
Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug... Read more...
| Press ReleasesMorphotek, Inc. and Pivotal BioSciences Announce Agreement for the Development of Therapeutic Monoclonal AntibodiesMorphotek, Inc. and Pivotal BioSciences Announce Agreement for the Development of Therapeutic Monoclonal Antibodies EXTON, Pa.--(BUSINESS Read more >> Status of the E2007 Development Program Status of the E2007 Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications Friday April 11 TOKYO, Japan, April 11 -- Read more >> PRESS RELEASE: EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION Tokyo, Japan, and Bloomington, MN, December 10, 2007 - Eisai Co., Ltd. (TSE: 4523.JP) ("Eisai"), a research-based Read more >> |
Get more Eisai coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
